Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1

Conditions

Paraproteinemias 1Neoplasms, Plasma Cell 1Multiple Myeloma 1Monoclonal Gammopathy of Undetermined Significance 1Leukemia, B-Cell 1Leukemia 1Immunoproliferative Disorders 1Immune System Diseases 1Hematologic Diseases 1Bronchiolitis Obliterans Syndrome 1Blood Protein Disorders 1

Interventions

Cyclophosphamide 119fludarabine phosphate 97Cytarabine 86fludarabine 74Methotrexate 70Rituximab 68Busulfan 56Whole-Body Irradiation 48Filgrastim 48Tacrolimus 43Mycophenolic Acid 43Antilymphocyte Serum 40Etoposide 37Peripheral Blood Stem Cell Transplantation 36Granulocyte Colony-Stimulating Factor 35Melphalan 34Vincristine 33Alemtuzumab 33Cyclosporine 32Clofarabine 30Azacitidine 30Dexamethasone 29Imatinib Mesylate 26thymoglobulin 25Doxorubicin 23sargramostim 22Lenalidomide 22Methylprednisolone 20Stem Cell Transplantation 19Daunorubicin 19

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia × Hsp90 inhibitor KU757 × Clear all
NCT01063907 2024-04-25

A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

Kyowa Kirin Co., Ltd.

Phase 1/2 Completed
95 enrolled 13 charts
LymphoidOther hematologic neoplasmPlasma cell

Bronchiolitis Obliterans Syndrome, Blood Protein Disorders, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, Paraproteinemias, Leukemia, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡